PH12015501914A1 - Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same - Google Patents

Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same

Info

Publication number
PH12015501914A1
PH12015501914A1 PH12015501914A PH12015501914A PH12015501914A1 PH 12015501914 A1 PH12015501914 A1 PH 12015501914A1 PH 12015501914 A PH12015501914 A PH 12015501914A PH 12015501914 A PH12015501914 A PH 12015501914A PH 12015501914 A1 PH12015501914 A1 PH 12015501914A1
Authority
PH
Philippines
Prior art keywords
methods
compositions
arylamino
inhibitors
mek
Prior art date
Application number
PH12015501914A
Other languages
English (en)
Inventor
Jean-Michel Vernier
Colin Edward Rowlings
Jean-Luc Girardet
Stuart Dimock
Barry Quart
Jeffrey N Miner
Original Assignee
Ardea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40304796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12015501914(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/830,733 external-priority patent/US8101799B2/en
Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc
Publication of PH12015501914A1 publication Critical patent/PH12015501914A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N41/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom
    • A01N41/02—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom containing a sulfur-to-oxygen double bond
    • A01N41/04—Sulfonic acids; Derivatives thereof
    • A01N41/06—Sulfonic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/28—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
PH12015501914A 2007-07-30 2015-08-28 Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same PH12015501914A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11/830,733 US8101799B2 (en) 2005-07-21 2007-07-30 Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
US3446608P 2008-03-06 2008-03-06
US3446408P 2008-03-06 2008-03-06
US4488608P 2008-04-14 2008-04-14
PCT/US2008/071392 WO2009018233A1 (en) 2007-07-30 2008-07-28 Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same

Publications (1)

Publication Number Publication Date
PH12015501914A1 true PH12015501914A1 (en) 2017-07-31

Family

ID=40304796

Family Applications (1)

Application Number Title Priority Date Filing Date
PH12015501914A PH12015501914A1 (en) 2007-07-30 2015-08-28 Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same

Country Status (22)

Country Link
EP (1) EP2184984A4 (enExample)
JP (3) JP2010535232A (enExample)
KR (3) KR20150091434A (enExample)
CN (2) CN101808516B (enExample)
AP (1) AP2817A (enExample)
AU (2) AU2008282338B2 (enExample)
BR (1) BRPI0815659A2 (enExample)
CA (1) CA2693390C (enExample)
CO (1) CO6470808A2 (enExample)
CR (1) CR11244A (enExample)
DO (1) DOP2010000045A (enExample)
EA (2) EA020624B1 (enExample)
EC (1) ECSP109910A (enExample)
HN (1) HN2010000203A (enExample)
IL (1) IL203296A (enExample)
MA (1) MA31881B1 (enExample)
MX (1) MX2010001244A (enExample)
NZ (1) NZ582929A (enExample)
PH (1) PH12015501914A1 (enExample)
SV (1) SV2010003469A (enExample)
TN (1) TN2010000049A1 (enExample)
WO (1) WO2009018233A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
BRPI0911297A2 (pt) * 2008-04-14 2019-09-24 Ardea Biosciences Inc composição e métodos para preparo e uso das mesmas
AU2009290988B2 (en) * 2008-09-09 2016-01-28 F. Hoffmann-La Roche Ag Polymorphs of acyl sulfonamides
CN105079805A (zh) 2008-09-26 2015-11-25 昂考梅德药品有限公司 卷曲蛋白结合药剂及其应用
KR20110132371A (ko) 2009-03-11 2011-12-07 아디아 바이오사이언스즈 인크. Ｒｄｅａ１１９／ｂａｙ ８６９７６６을 포함하는 특정 암의 치료를 위한 제약 조합물
UY32486A (es) * 2009-03-11 2010-10-29 Ardea Biosciences Inc Tratamiento del cáncer de páncreas
CA2814617C (en) 2009-10-13 2017-12-19 Allostem Therapeutics Llc Novel mek inhibitors, useful in the treatment of diseases
CA2777304A1 (en) * 2009-10-21 2011-04-28 Marion Hitchcock Substituted benzosulphonamides
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
CN102020651B (zh) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-芳基氨基吡啶酮甲酰胺mek抑制剂
CN102649773A (zh) * 2011-02-23 2012-08-29 苏州波锐生物医药科技有限公司 氨基芳香烃类化合物及其在制备抗恶性肿瘤药物中的用途
WO2012149493A2 (en) * 2011-04-28 2012-11-01 Sloan-Kettering Institute For Cancer Research Hsp90 combination therapy
AR086553A1 (es) * 2011-05-27 2014-01-08 Bayer Ip Gmbh Sintesis quiral de n-{3,4-difluoro-2-[(2-fluoro-4-yodofenil)amino]-6-metoxifenil}-1-[2,3-dihidroxi-propil]ciclopropano sulfonamidas
EP2788378A4 (en) * 2011-12-09 2015-09-09 Oncomed Pharm Inc ASSOCIATION THERAPY FOR THE TREATMENT OF CANCER
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
WO2013178581A1 (en) * 2012-05-31 2013-12-05 Bayer Pharma Aktiengesellschaft Biomarkers for determining effective response of treatments of hepatocellular carcinoma (hcc) patients
US9296753B2 (en) * 2012-06-04 2016-03-29 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
SI3702351T1 (sl) * 2012-10-19 2024-03-29 Array Biopharma Inc., Formulacija, ki obsega inhibitor mek
US20150265679A1 (en) 2012-11-02 2015-09-24 The United States Of America, As Represented By Secretary, Department Of Health And Human Services Method of reducing adverse effects in a cancer patient undregoing treatment with a mek inhibitor
AU2014212081A1 (en) 2013-02-04 2015-08-13 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
EP2848246A1 (en) 2013-09-13 2015-03-18 Bayer Pharma Aktiengesellschaft Pharmaceutical compositions containing refametinib
US9629851B2 (en) 2013-09-20 2017-04-25 Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis ROCK in combination with MAPK pathway
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
US20170027940A1 (en) 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
WO2015196072A2 (en) 2014-06-19 2015-12-23 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
US11197896B2 (en) 2014-08-25 2021-12-14 Société des Produits Nestlé S.A. Egg protein formulations and methods of manufacture thereof
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
JP7045726B2 (ja) 2017-06-16 2022-04-01 ベータ ファーマ，インコーポレイテッド Ｎ－（２－（２－（ジメチルアミノ）エトキシ）－４－メトキシ－５－（（４－（１－メチル－１ｈ－インドール－３－イル）ピリミジン－２－イル）アミノ）フェニル）アクリルアミドおよびその塩の医薬品製剤
JP2022526713A (ja) 2019-03-21 2022-05-26 オンクセオ がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子
US20220380348A1 (en) * 2019-10-04 2022-12-01 Sumitomo Dainippon Pharma Oncology, Inc. Axl inhibitor formulations
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
CN118834328B (zh) * 2024-07-02 2025-09-16 江苏海洋大学 金属蛋白酶9抗原决定基印迹纳米颗粒的制备方法及应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162117A (en) * 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
JP2575590B2 (ja) * 1992-07-31 1997-01-29 塩野義製薬株式会社 トリアゾリルチオメチルチオセファロスポリン塩酸塩およびその水和物結晶ならびにそれらの製法
ES2177868T3 (es) * 1992-08-25 2002-12-16 Searle & Co Hidroxietilaminosulfonamidas de alfa- y beta-aminoacidos utiles como inhibidores de proteasas retroviricas.
US7115632B1 (en) * 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
WO2000042029A1 (en) * 1999-01-13 2000-07-20 Warner-Lambert Company 1-heterocycle substituted diarylamines
GB0003224D0 (en) * 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
KR20040062546A (ko) * 2001-09-24 2004-07-07 제시 엘. 에스. 에이유 병용 요법에 이용되는 수라민의 약제감작화 용량을결정하는 방법 및 조성물
JP2006502117A (ja) * 2002-07-17 2006-01-19 タイタン ファーマシューティカルズ インコーポレイテッド 抗腫瘍活性を上昇させるための化学療法薬物の組み合わせ
KR20110102485A (ko) * 2002-07-30 2011-09-16 아에테르나 젠타리스 게엠베하 항종양 약제와 조합하여 사용하기 위한 알킬포스포콜린의 약물 제품
JP2008535924A (ja) * 2005-04-12 2008-09-04 エラン ファーマ インターナショナル リミテッド ナノ粒子キナゾリン誘導体製剤
JPWO2006115154A1 (ja) * 2005-04-22 2008-12-18 キッセイ薬品工業株式会社 ４´−｛２−［（１ｓ，２ｒ）−２−ヒドロキシ−２−（４−ヒドロキシフェニル）−１−メチルエチルアミノ］エトキシ｝−３−イソプロピル−３´，５´−ジメチルビフェニルカルボン酸塩酸塩の結晶多形
CA2618218C (en) * 2005-07-21 2015-06-30 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek
JP2007099763A (ja) * 2005-09-08 2007-04-19 Toyama Chem Co Ltd ピペラシリンナトリウム・１水和物の新規な結晶及びその製造方法
TW200800150A (en) * 2005-12-21 2008-01-01 Organon Nv Compounds with medicinal effects due to interaction with the glucocorticoid receptor

Also Published As

Publication number Publication date
CA2693390A1 (en) 2009-02-05
JP2015078199A (ja) 2015-04-23
MA31881B1 (fr) 2010-12-01
EP2184984A4 (en) 2013-07-24
KR20150091434A (ko) 2015-08-10
CN101808516A (zh) 2010-08-18
EA020624B1 (ru) 2014-12-30
HN2010000203A (es) 2012-11-19
AU2008282338B2 (en) 2015-02-12
JP6309880B2 (ja) 2018-04-11
JP2017125021A (ja) 2017-07-20
CN103479604A (zh) 2014-01-01
EA201000268A1 (ru) 2010-08-30
MX2010001244A (es) 2010-08-31
CA2693390C (en) 2017-01-17
BRPI0815659A2 (pt) 2014-09-30
IL203296A (en) 2017-06-29
EA032294B1 (ru) 2019-05-31
WO2009018233A1 (en) 2009-02-05
KR20100092424A (ko) 2010-08-20
DOP2010000045A (es) 2010-10-31
ECSP109910A (es) 2010-04-30
HK1147396A1 (en) 2011-08-12
SV2010003469A (es) 2010-04-30
CN103479604B (zh) 2016-08-10
NZ582929A (en) 2012-03-30
EP2184984A1 (en) 2010-05-19
KR20140098185A (ko) 2014-08-07
AP2817A (en) 2013-12-31
EA201400552A1 (ru) 2014-09-30
CO6470808A2 (es) 2012-06-29
TN2010000049A1 (en) 2011-09-26
CR11244A (es) 2010-05-20
AU2015200390B2 (en) 2017-02-23
JP2010535232A (ja) 2010-11-18
AU2008282338A1 (en) 2009-02-05
AP2010005134A0 (en) 2010-02-28
CN101808516B (zh) 2013-08-28

Similar Documents

Publication Publication Date Title
PH12015501914A1 (en) Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same
UA99731C2 (ru) Кристаллические полиморфные формы n-(ариламино)сульфонамидов как ингибиторы мэк, композиция (варианты) и применение
NO2023022I1 (no) cobimetinib, optionally in any form protected by the basic patent, including harmaceutically acceptable salts and sovates thereof, particularly cobimetinib hemifumarate
CY1122808T1 (el) Ενωσεις ετεροαρυλιου χρησιμες ως αναστολεις toy ενζυμου ενεργοποιησης της sumo
EP3483143A8 (en) Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer
WO2010053583A3 (en) Small molecule cd4 mimetics and uses thereof
GEP20105074B (en) Pyrimidinyl aryl urea derivatives being fgf inhibitors
MX2012007273A (es) Pteridinonas como inhibidores de la quinasa tipo polo.
MY139399A (en) Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
IN2012DN03085A (enExample)
MX2009000884A (es) Derivados de piridizinona.
TW200640883A (en) Compounds for the treatment of proliferative disorders
CY1122201T1 (el) Παραγωγα βενζοδιοξολιου ως αναστολεις φωσφοδιεστερασης
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
WO2012048129A3 (en) Inhibitors of polo-like kinase
WO2010145197A8 (en) Novel 6-arylamino pyridone sulfonamides and 6-arylamino pyrazinone sulfonamdies as mek inhibitors
SE0400284D0 (sv) Novel compounds
MX2011011776A (es) Nuevos profarmacos de triptolite.
WO2007143523A8 (en) Fused, tricyclic sulfonamide inhibitors of gamma secretase
MY194116A (en) Pharmaceutical compounds
TW200420541A (en) Crystalline forms
MX2012006822A (es) 1,7-diazacarbazoles y metodos de uso.
MX378555B (es) Proceso para la preparacion de derivados del acido biliar de las sulfonilureas
MX2020002430A (es) Compuestos inhibidores del receptor 1 del acido lisofosfatidico (lpar1).
NO20073725L (no) CCI-779-polymorf og dens anvendelse